Apogee Therapeutics (APGE) Cash from Financing Activities (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Cash from Financing Activities data on file, last reported at $411.2 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 66004.02% year-over-year to $411.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $807.0 million (up 1685.04% YoY) and the FY2025 annual result came in at $396.5 million, down 19.92% from the prior year.
• Cash from Financing Activities rose to $411.2 million in Q1 2026 per APGE's latest filing, from $375.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $450.5 million in Q1 2024 and bottomed at -$213000.0 in Q4 2023.
• The 5-year median for Cash from Financing Activities is $19.7 million (2025), against an average of $137.2 million.
• The widest annual swing landed in 2023, when Cash from Financing Activities slumped 100.13%; it then surged 66004.02% in 2026.
• Tracing APGE's Cash from Financing Activities over 5 years: stood at $158.5 million in 2022, then slumped by 100.13% to -$213000.0 in 2023, then jumped by 20924.41% to $44.4 million in 2024, then soared by 745.32% to $375.0 million in 2025, then rose by 9.66% to $411.2 million in 2026.
• Per Business Quant, the three latest APGE Cash from Financing Activities figures stand at $411.2 million (Q1 2026), $375.0 million (Q4 2025), and $19.7 million (Q3 2025).

Peer Comparison